UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 12, 2020
FOAMIX PHARMACEUTICALS LTD.
(Exact name of registrant as specified in its charter)
|
Israel
|
001-36621
|
N/A
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
2 Holzman Street,
Weizmann Science Park
|
|
|
|
|
Rehovot, Israel
|
7670402
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
|
|
+972-8-9316233
|
|
(Registrant’s telephone number, including area code)
|
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
Title of each class
|
Ticker symbol(s)
|
Name of each exchange on which registered
|
|
Ordinary Shares, par value NIS 0.16 per share
|
FOMX
|
Nasdaq Global Stock Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On March 12, 2020, Menlo Therapeutics Inc. (“Menlo”) issued a press release announcing the financial results for the
year ended December 31, 2019 for its wholly-owned subsidiary, Foamix Pharmaceuticals Ltd. (the “Company”). A copy of the press release is furnished as Exhibit 99.1 hereto.
The information in this Item 2.02 and Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act,
except as expressly set forth by specific reference in such filing.
Item 7.01 Regulation FD Disclosure
On March 12, 2020, Menlo issued a press release announcing the financial results for the year ended December 31, 2019
for the Company. A copy of the press release is furnished as Exhibit 99.1 hereto.
The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of
that section, nor shall they be deemed incorporated by reference in any of the Company’s filings under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 12, 2020
|
|
FOAMIX PHARMACEUTICALS LTD.
|
|
|
|
|
|
|
|
By:
|
/s/ Mutya Harsch
|
|
|
|
|
Mutya Harsch
|
|
|
|
|
Chief Legal Officer
|
|
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
